Patent Application
20250066863
The subject matter described herein relates to methods to determine a treatment protocol in a subject clinically diagnosed with otitis media and to methods to diagnose and/or treat otitis media.
Otitis media, which includes acute otitis media (AOM), chronic otitis media, otitis media with effusion, secretory otitis media, and chronic secretory otitis media as examples, is a condition affecting both adults and children. Clinically, acute otitis media is defined by an abrupt onset of middle ear effusion and inflammation, diagnosed by various methods to visualize bulging of the tympanic membrane, and often including presence of effusion in the middle ear cavity. Bacterial infection accounts for a large percentage of otitis media cases. However, viruses, as well as other microbes, may also be causative agents. Because otitis media can be caused by a virus, bacteria, or both, it is often difficult to identify the exact cause and thus the most appropriate treatment.
Additionally, concerns about the development of antimicrobial resistance have led to recommendations to withhold antibiotics, unless symptoms persist or worsen, which is sometimes referred to as “observation” or a “watchful waiting strategy,” which can prolong the symptoms. Improved approaches for diagnosing the cause of otitis media are needed, to tailor the treatment accordingly.
The foregoing examples of the related art and limitations related therewith are intended to be illustrative and not exclusive. Other limitations of the related art will become apparent to those of skill in the art upon a reading of the specification and a study of the drawings.
The following aspects and embodiments thereof described and illustrated below are meant to be exemplary and illustrative, not limiting in scope.
In one aspect, a kit including a plurality of primers specific to each of beta-lactamase producing H. influenzae, non-beta-lactamase producing H. influenzae, M. catarrhalis, and S. pneumonia is provided. The primers specific to beta-lactamase producing H. influenzae and non-beta-lactamase producing H. influenzae are capable of amplifying at least one gene that encodes beta-lactamase.
In one aspect, a method to determine a treatment regimen in a subject clinically diagnosed with otitis media is provided. The method comprises determining presence or absence of H. influenzae, S. pneumoniae, and M. catarrhalis from a sample obtained from the subject, to obtain a test result, and analyzing the test result to assess one or more of (i) spontaneous resolution rate of each detected pathogen, (ii) presence of an antibiotic resistance marker, (iii) presence of an antibiotic resistant pathogen; and/or (iv) known antibiotic resistance patterns for detected otopathogens. Based on the analyzing, a treatment regimen for the subject to treat the otitis media, if present, is provided.
In another aspect, a method to determine a treatment protocol in a subject clinically diagnosed with otitis media is provided. The method comprises analyzing a test result indicating presence or absence of negative beta-lactamase H. influenzae, positive beta-lactamase H. influenzae. M. catarrhalis, and S. pneumoniae from a biological sample from the subject to determine if S. pneumonia is present or absent, wherein
In another aspect, a method to reduce antibiotic usage in subjects pathogenically diagnosed with otitis media, where the pathogenic diagnosis comprises a determination of presence or absence of negative beta-lactamase H. influenzae, positive beta-lactamase H. influenzae. M. catarrhalis, and S. pneumoniae is provided. The method comprises evaluating the pathogenic diagnosis to determine
In another aspect, a method for diagnosing and/or treating otitis media, comprises obtaining a test result from an assay performed on a biological sample from a subject that reports presence or absence of negative beta-lactamase H. influenzae, positive beta-lactamase H. influenzae, M. catarrhalis, and S. pneumoniae; applying a decision algorithm to the test result to determine a treatment protocol; administering, recommending administration of, or having administered the treatment protocol; and monitoring patient response to the treatment protocol.
In an embodiment, decision algorithm comprises any one of the algorithms shown in
In an embodiment, the decision algorithm comprises evaluating the test result to determine one or more of the following:
In another aspect, a computer-implemented method for diagnosing otitis media is provided, where the method comprises receiving a test result from an assay performed on a biological sample from a subject, wherein the test result reports presence or absence of positive beta-lactamase H. influenzae, positive beta-lactamase H. influenzae, S. pneumoniae, and M. catarrhalis; applying a decision algorithm to the test result to determine a treatment protocol, providing the treatment protocol to the subject, a medical caregiver, clinician, or pharmacist, wherein the decision algorithm comprises any one of the algorithms shown in
In an embodiment, the algorithm comprises determining if S. pneumonia is present or absent, wherein if S. pneumonia is present, then:
In an embodiment, the algorithm further comprises determining that S. pneumonia is absent, and if true (i.e., S. pneumonia is absent in a diagnostic test result) determining one or more of (c), (d), (e), (f) and (g):
In an embodiment, the algorithm further comprises providing or recommending a treatment based on the determining, wherein if
In another aspect, a method for detecting an otopathogen in a subject is provided. The method includes collecting a nasal sample from the subject, combining a portion of the nasal sample with an extraction reagent to produce a test sample, combining a portion of the test sample with an amplification reagent to produce an amplification sample including a portion of the test sample and reagents for amplification of otopathogen nucleic acid, amplifying otopathogen nucleic acid, if present, by polymerase chain reaction (PCR) or by an isothermal amplification technique, in the amplification sample to produce an amplified sample, and detecting amplified otopathogen nucleic acid, if present, in the amplified sample.
In another aspect, a method for identifying the etiology of acute otitis media in a clinically diagnosed subject is provided. The method includes collecting a nasal sample from the subject, combining a portion of the nasal sample with an extraction reagent to produce a test sample, combining a portion of the test sample with an amplification reagent to produce an amplification sample comprising a portion of the test sample and reagents for amplification of otopathogen nucleic acid, amplifying otopathogen nucleic acid, if present, by an amplification technique in the amplification sample to produce an amplified sample, detecting amplified otopathogen nucleic acid, if present, in the amplified sample. Detection of amplified otopathogen nucleic acid in the amplified sample confirms a clinical diagnosis of acute otitis media.
In another aspect, a method for detecting an otopathogen in a subject or for identifying the etiology of acute otitis media in a clinically diagnosed subject comprises collecting a sample from the subject; optionally, combining a portion of the sample with a reagent to produce a test sample; and detecting an otopathogen, if present, in the sample.
In an embodiment, detecting otopathogen comprises detection of a single nucleic acid, a single protein, or an amplified nucleic acid. In other embodiments, detecting comprises detecting an amplicon of the otopathogen in the sample.
In another aspect, a method for treating acute otitis media in a subject is provided. The method includes obtaining a nasal sample from the subject, combining a portion of the nasal sample or the test sample with an amplification reagent to produce an amplification sample comprising a portion of the test sample and reagents for amplification of otopathogen nucleic acid, amplifying otopathogen nucleic acid, if present, in the amplification sample to produce an amplified sample, and detecting amplified otopathogen nucleic acid, if present, in the amplified sample. Upon detection of amplified otopathogen nucleic acid, acute otitis media in the subject is treated with an antibiotic. The method may also include combining a portion of the nasal sample with an extraction reagent to produce a test sample.
In another aspect, a method for treating acute otitis media in a subject is provided. The method includes obtaining a sample from the subject and detecting an otopathogen, if present, in the sample. Upon detection of an otopathogen, acute otitis media in the subject is treated with an antibiotic or is recommended for no immediate antibiotic treatment. The method may also include combining a portion of the sample with a reagent to produce a test sample.
In another aspect, a method including providing a test input to a diagnostic and treatment system, the test input including data on the presence of absence of a plurality of otopathogens, the otopathogens including a positive beta-lactamase H. influenzae, a negative beta-lactamase H. influenzae, S. pneumoniae, and M. catarrhalis in a patient sample; and generating, via a treatment model implemented using a decision algorithm, at least one primary treatment protocol is provided.
In addition to the exemplary aspects and embodiments described above, further aspects and embodiments will become apparent by reference to the drawings and by study of the following descriptions.
Additional embodiments of the present methods, diagnostic assays, kits, systems, and the like will be apparent from the following description, drawings, examples, and claims. As can be appreciated from the foregoing and following description, each and every feature described herein, and each and every combination of two or more of such features, is included within the scope of the present disclosure provided that the features included in such a combination are not mutually inconsistent. In addition, any feature or combination of features may be specifically excluded from any embodiment of the present disclosure. Additional aspects and advantages of the present disclosure are set forth in the following description and claims, particularly when considered in conjunction with the accompanying examples and drawings.
Various aspects now will be described more fully. Such aspects may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey its scope to those skilled in the art.
For convenience, certain terms employed in the specification, examples, and claims are collected here. Unless defined otherwise, all technical and scientific terms used in this disclosure have the same meanings as commonly understood by one of ordinary skill in the art to which this disclosure belongs.
Where a range of values is provided, it is intended that each intervening value between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the disclosure. For example, if a range of 1 μm to 8 μm is stated, it is intended that 2 μm, 3 μm, 4 μm, 5 μm, 6 μm, and 7 μm are also explicitly disclosed, as well as the range of values greater than or equal to 1 μm and the range of values less than or equal to 8 μm.
The compositions of the present disclosure can comprise, consist essentially of, or consist of, the components disclosed.
The singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to a “polymer” includes a single polymer as well as two or more of the same or different polymers, reference to an “excipient” includes a single excipient as well as two or more of the same or different excipients, and the like.
The term “about,” particularly in reference to a given quantity, is meant to encompass deviations of plus or minus five percent.
“Antibiotic” means a compound that has the ability to destroy or inhibit microorganisms and is used to treat infectious disease. This encompasses compounds produced by microorganisms, semi-synthetic or synthetic compounds that are chemical derivatives of a compound produced by microorganisms, and semi-synthetic or synthetic compounds that act on specific biochemical pathways necessary for a cell's survival.
“Clinically” as in ‘clinically diagnosed’ intends a determination by a person, such as a medical provider or a caregiver, of otitis media based on physical presentation of signs and symptoms of otitis media, such as fever, ear pain, pulling at one or both ears, swelling and/or redness of eardrum, recent cold or respiratory infection, etc.
“Immediate” when used in the context of treating with an “immediate antibiotic” intends an antibiotic (or a prescription for an antibiotic) that is given to a subject or patient to be taken right away or as soon as practicable, or in the case of a prescription for an antibiotic, that is to be filled right away or as soon as practicable, in order to take the antibiotic right away or as soon as practicable.
“Otitis media” as used herein includes, without limitation, otitis media, acute otitis media, otitis media with effusion, secretory otitis media, and chronic secretory otitis media
“Otitis inflammation” and “ear infection” as used herein include, without limitation, otitis media and otitis externa.
The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, salts, compositions, dosage forms, etc., which are—within the scope of sound medical judgment—suitable for use in contact with the tissues of human beings and/or other mammals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. In some aspects, “pharmaceutically acceptable” means approved by a regulatory agency of the federal or a state government, or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals (e.g., mammals), and more particularly, in humans.
The term “treating” is used herein, for instance, in reference to methods of treating otitis media, and generally includes the administration of a compound or composition which reduces or ameliorates the signs and symptoms of the medical condition, or reduces the frequency of or delays the progression of a medical condition (e.g., otitis media) in a subject relative to a subject not receiving the compound or composition. This can include reversing, reducing, or arresting the symptoms, clinical signs, and/or underlying pathology of a condition in a manner to improve or stabilize a subject's condition.
By reserving the right to proviso out or exclude any individual members of any such group, including any sub-ranges or combinations of sub-ranges within the group, that can be claimed according to a range or in any similar manner, less than the full measure of this disclosure can be claimed for any reason. Further, by reserving the right to proviso out or exclude any individual substituents, analogs, compounds, ligands, structures, or groups thereof, or any members of a claimed group, less than the full measure of this disclosure can be claimed for any reason.
Throughout this disclosure, various patents, patent applications, and publications are referenced. The disclosures of these patents, patent applications and publications in their entireties are incorporated into this disclosure by reference in order to more fully describe the state of the art as known to those skilled therein as of the date of this disclosure. This disclosure will govern in the instance that there is any inconsistency between the patents, patent applications, and publications cited and this disclosure.
Otitis media can be caused by a virus, bacteria, or both. The methods and diagnostic assays provided herein provide for identification of the cause(s) of the infection and a decision algorithm to determine a treatment regimen or protocol based on the identified cause(s).
Suitable samples (specimens) for use in the diagnostic assays disclosed herein include biological material obtained from the nose, ear, or eye of a subject (patient). A sample from the nose (nasal sample) may be a nasopharyngeal sample, an anterior naris sample, an inferior turbinate sample, a middle turbinate sample, or a superior turbinate sample. Biological material may include fluid and mucous. Fluid may be as sputum, oropharyngeal, saliva, middle or inner ear fluid, or fluid leaking from a ruptured tympanic membrane. Mucous may be nasal or conjunctival. Samples may be obtained by swabbing, wiping, or otherwise collecting biological material. Samples may be obtained indirectly, such as from surgical instruments used to place an ear tube (e.g., myringotomy tube or tympanostomy tube) or from a tube itself. When a sample obtained from other than the ear is used in the assays disclosed herein to determine the bacteria and/or virus causative of otitis media, the bacteria and/or virus in the sample is representative of the bacteria and/or virus in the ear. A sample, or a portion thereof, may be combined with an extraction reagent to produce a test sample, such as for use in an assay.
In some embodiments, samples can be analyzed for the presence of pathogens, such as otopathogens, by diagnostic assays including molecular assays. Compared to known assays and methods for diagnosing otitis media, the presently disclosed assay's may not include culturing a sample, such as to grow and then interrogate pathogens in the sample. A determination of the causative agent may be made without growing or attempting to grow any organism. Compared to known assays and methods for diagnosing otitis media, the presently disclosed assays may be free of samples obtained from the ear. The presently discloses assays may utilize samples obtained from bodily regions other than the ear, such as the nose or nasopharynx. Compared to known methods of diagnosing otitis media via a sample from the ear, obtaining a nasal or nasopharyngeal sample may be easier, less invasive, and/or less painful.
The assays disclosed herein may be as sensitive as, or more sensitive than, known otitis media assays, such as those that include culturing a sample. The sensitivity of the assays disclosed herein may be as high as, or higher than, known otitis media assays. The presently disclosed assays may take less time to run, and/or produce results faster, than known assays. For example, results from a presently disclosed assay may be available in one to several hours, and the results from culturing a sample may be available in one to several days. The assays disclosed herein may also be less expensive to run that known assays.
Diagnostic assays include, but are not limited to, assays which comprise amplification and detection of target nucleic acid sequences, such as sequences present in the genomes of pathogens and/or otopathogens. Other diagnostic assays contemplated herein do not require amplification of target pathogen nucleic acid prior to detection of such pathogenic genetic materials.
For example, in some embodiments, the diagnostic assays for otopathogen detection provided herein comprise polymerase chain reaction (PCR) based assays. PCR amplifies a specific target region of a DNA strand (the DNA target) that may be present in the samples of the present technology. If a particular otopathogen is present in a sample, then nucleic acids specific to said otopathogen can be amplified and detected with primers and probes specific for the pathogen.
As understood by one of skill in the molecular diagnostic arts, in some embodiments, a PCR-based assay comprises a polymerase, primers complementary to the DNA target (such as otopathogenic nucleic acids), and deoxynucleoside triphosphates (dNTPs) present in a suitable buffer for nucleic acid amplification and detection.
To initiate a diagnostic assay as described herein, a sample is collected and placed in suitable media to produce a test sample for storage, transport, extraction, and/or analysis. Alternatively or additionally, a sample may be combined with an extraction reagent to produce a test sample. A portion of the test sample can then be used as the basis for diagnostic analysis. The test sample, or portion thereof, may be combined with one or more reagents, such as an amplification reagent, for use in diagnostic analysis. The analysis may be by molecular assays including PCR analysis. PCR-based analyses, as described herein, include any PCR-based assays as understood by one skilled in the molecular biological arts.
For example, in some embodiments, the diagnostic assays of the present technology may include, but not be limited to, reverse transcription PCR (RT-PCR), real-time RT-PCR, isothermal PCR, multiplex PCR, and/or single cell sequencing. RT-PCR is a laboratory technique combining reverse transcription of RNA into DNA (in this context called complementary DNA or cDNA) and amplification of specific DNA targets using PCR. Multiplex polymerase chain reaction (multiplex PCR) refers to the use of polymerase chain reaction to amplify several different DNA sequences simultaneously (as if performing many separate PCR reactions all together in one reaction). Isothermal amplification methods provide detection of a nucleic acid target sequence in a streamlined, exponential manner, and are not limited by the constraint of thermal cycling. Single-cell sequencing involves isolating a single cell, amplifying the whole genome or region of interest, constructing sequencing libraries, and then applying next-generation DNA sequencing.
Accordingly, as described herein, the present technology includes utilizing the diagnostic assays described above for analysis of a sample, such as a nasal or nasopharyngeal sample, for the presence of pathogens, including, but not limited to, otopathogens, such as H. influenzae, M. catarrhalis, and/or S. pneumoniae. In some embodiments, the diagnostic assays described herein provide identification of various strains of pathogens, such as whether the pathogen expresses beta-lactamase or not.
In an embodiment, the diagnostic assay is a point-of-care assay, which allows patients, physicians, and care teams to receive test results quickly, which allows for better and more immediate clinical management decisions to be made. Point-of-care testing may be defined as medical diagnostic testing that is performed at a location where care or other treatment is provided. A point-of-care system or device may be located, for example, in a hospital, nursing home, clinic, or in the home of an individual patient. Point-of-care testing may also be referred to herein as near-patient testing, remote testing, satellite testing, and/or rapid diagnostics testing.
The present technology includes diagnostic, such as molecular diagnostic, assays for detection of pathogens from patient samples such as nasal and/or nasopharyngeal samples. In some embodiments, the diagnostic assays include PCR-based assays comprising oligonucleotides, such as primers and probes, for amplification and/or analysis and/or detection of pathogenic nucleic acids. In some embodiments the pathogens analyzed/detected by the current technology comprise otopathogens, including H. influenzae, M. catarrhalis, or S. pneumoniae. Accordingly, the current technology provides primers and probes for the analysis of otopathogens including H. influenzae, M. catarrhalis, or S. pneumoniae.
Specifically, in embodiments, the present technology is related to oligonucleotides, such as probes and primers for amplification and/or analysis of H. influenzae, such as the sequences and primers associated with H. influenzae as described in US Patent Application Publication No. 2010/0034822, incorporated by reference herein. For example, oligonucleotides, such as primers and probes, for H. influenzae may be directed to amplification and/or analysis/detection of any of the nucleic acid portions of H. influenzae provided in the odd SEQ ID NOs between 1 and 3706 of US Patent Application Publication No. 2010/0034822.
Specifically, in embodiments, the present technology is related to oligonucleotides, such as probes and primers for amplification and/or analysis of M. catarrhalis, such as the sequences and primers associated with M. catarrhalis as described in US Patent Application Publication No. 2007/0010665, incorporated by reference herein. For example, oligonucleotides, such as primers and probes, for M. catarrhalis may be directed to amplification and/or analysis/detection of any of the nucleic acid portions of S. pneumoniae provided in Table 2 of US Patent Application Publication No. 2007/0010665.
Specifically, in embodiments, the present technology is related to oligonucleotides, such as probes and primers for amplification and/or analysis of S. pneumoniae, such as the sequences and primers associated with S. pneumoniae as described in US Patent Application Publication No. 2007/0009900, incorporated by reference herein. For example, oligonucleotides, such as primers and probes, for S. pneumoniae may be directed to amplification and/or analysis/detection of any of the nucleic acid portions of S. pneumoniae provided in SEQ ID NO: 1-SEQ ID NO: 2661 or in Table 2 of US Patent Application Publication No. 2007/0009900.
A sample, as disclosed herein, may be subjected to an assay disclosed herein and the results, which may be presented in a report, may indicate the presence of absence of an otopathogen.
The pathogenic agents, also referred to as otopathogens, can be bacterial or viral. Bacterial otopathogens include, for example, Haemophilus influenzae (H. influenzae), Moraxella catarrhalis (M. catarrhalis), Streptococcus pneumoniae (S. pneumoniae), Streptococcus pyogenes, Staphylococcus intermedius, Staphylococcus epidermidis, Staphylococcus aureus, Staphylococcus caprae, Staphylococcus auriculis, Staphylococcus capitis, Staphylococcus haemolytis, Pseudomonas aeroginosa, Proteus mirabilis, Proteus vulgaris, Escherichia faecalis, and/or Escherichia coli.
Accordingly, in an embodiment, a diagnostic assay with reagents to determine presence or absence of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more pathogenic agents is provided.
Moraxella catarrhalis (M. catarrhalis) is a Gram-negative diplococcus frequently found as a commensal of the upper respiratory tract.
Haemophilus influenzae (H. influenzae) is a Gram-negative, facultatively anaerobic coccobacillus. Depending on the presence of a polysaccharide capsule, isolates of H. influenzae are divided into encapsulated and non-encapsulated strains. There are six types of encapsulated strains designated a-f, which express distinct capsular polysaccharides, and which can be differentiated by their ability to agglutinate with antisera against the respective polysaccharide. Non-encapsulated H. influenzae strains are termed nontypable H. influenzae. Typing systems include biotyping, classification of outer membrane protein molecular weight, genetic classification by electrophoresis or PCR, and others.
Some isolates of H. influenzae are beta-lactamase positive, producing one or more beta-lactamase enzymes. Beta-lactamase may provide resistance to beta-lactam antibiotics. Other isolates of H. influenzae are beta-lactamase negative and do not produce beta-lactamase. Reference herein to a negative beta-lactamase H. influenzae intends an isolate of H. influenzae that does not or is unlikely to produce (or express) beta-lactamase. A negative beta-lactamase H. influenzae may carry a gene for beta-lactamase but not produce or express beta-lactamase. Reference herein to a positive beta-lactamase H. influenzae intends an isolate of H. influenzae that expresses (or produces) or is likely to express or produce beta-lactamase. A positive beta-lactamase H. influenzae carries a gene for beta-lactamase. A positive beta-lactamase H. influenzae isolate may be TEM-1 or ROB-1. In an embodiment, H. influenzae that does not or is unlikely to produce beta-lactamase is referred to as a “non-beta lactamase producing H. influenzae” or a negative beta-lactamase H. influenzae. In an embodiment, H. influenzae that produces beta-lactamase or is likely to produce beta-lactamase is referred to as a “beta-lactamase producing H. influenzae” or a positive beta-lactamase H. influenzae. As can be appreciated, and as described infra, a diagnostic assay can be capable of a genomic identification, to distinguish, differentiate, and/or identify with specificity a type, subtype, isolate, or strain of H. influenzae, including whether it carries a beta-lactamase gene. Other diagnostic assays can be configured to be a phenotypic indicator of H. influenzae type, subtype, isolate, or strain, and/or can be used for determining presence or absence of beta-lactamase, in order to determine whether an isolate or strain of H. influenzae in a sample is a positive beta-lactamase H. influenzae or a negative beta-lactamase H. influenzae.
In one embodiment, bacterial otopathogens are selected from gram-positive bacteria and gram-negative bacteria. The gram-positive bacteria are selected from one or more of Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus agalactiae, Streptococcus pneumoniae, Streptococcus pyogenes, Enterococcus spp., and Clostridium difficile. The gram-negative bacteria are selected from one or more of Citrobacter spp., Citrobacter freundii, Enterobacter cloacae, Klebsiella pneumoniae, Escherichia coli, Proteus vulgaris, Salmonella spp., Serratia marcescens, Shigella spp., Pseudomonas aeruginosa, Moraxella mucositis, Neisseria gonorrhoeae, Neisseria meningitidis, Acinetobacter spp., Burkholderia spp., Campylobacter spp., Helicobacter pylori, Vibrio cholerae, Klebsiella pneumoniae, Haemophilus influenzae, Mycobacterium avium complex, Mycobacterium abscessus, Mycobacterium kansasii, Mycobacterium ulcerosa, Chlamydophila pneumoniae, Chlamydia trachomatis, β-hemolytic Streptococcus, Acinetobacter baumannii, Pesudomonas pyocyaneum, Bacteroides fragilis, Bacillus cereus, and Stenotrophomonas maltophilia.
In one embodiment, a bacterial otopathogen carriers one or more antimicrobial resistance markers, such as ctx-M (blaCTX-M, subgroup 1), kpc (blaKPC), mecA, ndm (blaNDM), oxa-23 (blaOXA-23), oxa-24 (blaOXA-24), oxa-48 (blaOXA-48), oxa-58 (blaOXA-58), tem (blaTEM), and vim (blaVIM).
In one embodiment, viral otopathogens are, for example, Influenza A, Influenza B. Rhinovirus, SARS-CoV-2, a rhinovirus, Middle East respiratory syndrome-coronavirus (MERS-CoV), a coronavirus, or a respiratory syncytial virus (RSV).
Antibiotics for managing and/or treating otitis media are now described.
Bactericidal antibiotics kill a bacteria, usually by interfering with the formation of a bacterial cell wall or its contents. A bacteriostatic antibiotic will stop a bacterial from multiplying. There are numerous different antibiotics, many of which can be classified as shown in the following groups.
Penicillins: ampicillin, amoxicillin with clavulanic acid (co-amoxiclav), dicloxacillin, flucloxacillin, nafcillin, oxacillin, penicillin, penicillin V, penicillin G, phenoxy methylpenicillin
Cephalosporins: cefaclor, cefazolin, cefadroxil, cephalexin (cefalexin), cefuroxime, cefixime, cefoxitin, ceftriaxone
Aminoglycosides: gentamicin, tobramycin
Tetracyclines: doxycycline, lymecycline, minocycline, sarecycline, tetracycline
Macrolides: azithromycin, clarithromycin, clindamycin, erythromycin, fidaxomicin, roxithromycin
Fluoroquinolones: ciprofloxacin, levofloxacin, moxifloxacin, ofloxacin; these are generally broad-spectrum antibiotics that have been used to treat a wide range of infections, especially respiratory and urinary tract infections.
Sulfonamindes: sulfamethoxazole with trimethoprim, sulfasalazine, sulfacetaminde, sulfadiazine silver.
Other antibiotics include chloramphenicol (often used for eye and ear infections), fusidic acid (often used for skin and eye infections), and nitrofurantoin and trimethoprim (often used for urinary tract infections).
Broad-spectrum antibiotics are those that act on the two major bacterial groups—gram-positive and gram-negative—or any antibiotic that acts against a wide range of disease-causing bacteria. Examples include doxycycline, minocycline, aminoglycosides (except for streptomycin), ampicillin, amoxicillin, amoxicillin/clavulanic acid (Augmentin), azithromycin, carbapenems (e.g. imipenem), piperacillin/tazobactam, quinolones (e.g., ciprofloxacin), tetracyclines, chloramphenicol, ticarcillin, and trimethoprim/sulfamethoxazole (Bactrim). Narrow-spectrum antibiotics are those that are effective against only a specific group of bacteria, such as findaxomicin and sarecycline.
Table A provides non-limiting antibiotic options for use with the methods described herein. As seen in Table A, a first treatment protocol is to provide or recommend to provide a narrow-spectrum antibiotic and/or an antibiotic that does not require beta-lactamase activity. Non-limiting examples of antibiotics for use in a treatment or treatment protocol where an antibiotic that does not require beta-lactamase activity is provided or recommended include amoxicillin, penicillin V, and phenoxymethylpenicillin. In embodiments, the narrow-spectrum antibiotic and/or an antibiotic that does not require beta-lactamase activity is selected from penicillin V, cefdinir, cefuroxime, cefpodoxime, ceftriaxone, and cefixime; 2nd and 3rd line cephalosporins, such as cefprozil, cefuroxime-axetil, ceftriaxone; cefdinir, cefuroxime, cefpodoxime, ceftriaxone, cefixime, co-trimoxazole, cefaclor, cefuroximexetil, clarithromycin, trimethoprim-sulfamethoxazole; and cefditoren pivoxil, cefaclor, cephalexin, ceftriaxone, cefdinir, tebipenem pivoxil, tosfloxacin, ampicillin, cefpodomixine, clindamycin, trimethoprim-sulfamethoxazole, cefuroxime, and cloxacillin.
Another treatment protocol is to provide or recommend to provide a broad-spectrum antibiotic that has beta-lactamase activity. Examples of antibiotics having or with beta-lactamase activity include amoxicillin-clavulanate, cefuroxime axetil or other 2nd generation cephalosporins, and ceftriaxone. In other embodiments, the broad spectrum antibiotic or antibiotic having or with beta-lactamase activity for use in a treatment or treatment protocol where an antibiotic with or having beta-lactamase activity is provided or recommended is selected from cefdinir, cefuroxime, cefpodoxime, ceftriaxone, and cefixime; 3rd generation cephalosporins (e.g. ceftriaxone); clarithromycin, erythromycin, trimethoprim-sulfamethoxazole, cefdinir, cefuroxime, cefpodoxime, ceftriaxone, cefixime, co-trimoxazole, cefaclor, cefuroximexetil, clarithromycin, trimethoprim-sulfamethoxazole, and fluoroquinolones including levofloxacin. In another embodiment, the broad spectrum antibiotic that has beta-lactamase activity is selected from amoxicillin-clavulanate, cefditoren pivoxil, ceftriaxone, cefuroxime, cefaclor, cefdinir, tebipenem pivoxil, tosfloxacin, cefpodomixine, clindamycin, trimethoprim-sulfamethoxazole, and cloxacillin.
S. pneumoniae resistance), doxycycline
S. pneumoniae resistance), doxycycline
H. influenzae activity), erythromycin-sulfisoxazole
The antibiotic can be provided or administered in a liquid or solid form. Tablets, capsules, a liquid, a suspension, a dispersion, a spray, and drops are contemplated. Ear drops may be used as the vehicle for administration of the antibiotic. In the case that ear swelling has progressed substantially and ear drops do not penetrate significantly into the ear canal, a wick can be inserted into the ear canal to facilitate penetration of the treatment solutions. It is also contemplated to provide a therapeutic agent other than an antibiotic, such as a pain relief medication or an antiviral agent.
Antibiotics with β-lactamase activity can include penicillins, cephalosporins, monobactams, carbapenems, and penemase inhibitors. Specifically, the β-lactam antibiotics include penicillin, oxacillin, cloxacillin, dicloxacillin, flucloxacillin, ampicillin, pivampicillin, amoxicillin, carbenicillin, furbenicillin, sulbenicillin, ticarcillin, piperacillin, mecillinam, cephalothin, cephaloridine, cefazolin, cefradine, cefuroxime, cefaclor, cefotaxime, ceftriaxone, ceftazidime, cefoperazone, cefoxitin, imipenem, aztreonam, and the like.
Treatment options include antibiotics or surgical intervention, including myringotomy, an operation to insert a tympanostomy tube through the tympanic membrane and into the patient's middle ear to drain the fluid and balance the pressure between the outer and middle ear. Antipyretics and analgesics, including benzocaine, ibuprofen, and acetaminophen, may also be prescribed to treat accompanying fever or pain symptoms. Antivirals can be administered if the diagnostic test result indicates presence of a virus.
Continuing with the
In an embodiment, for subjects with no S. pneumonia nor H. influenzae (of either subtype), and with M. catarrhalis present in the diagnostic test result or report, and where an antibiotic was not recommended or provided, with or without a recommendation for a follow-up, if the subject does not improve or worsens in a certain time frame, then a rescue antibiotic is provided or recommended, where the rescue antibiotic is one having beta-lactamase activity.
Accordingly, provided is a method to reduce antibiotic usage in subjects pathogenically diagnosed with otitis media, where the pathogenic diagnosis includes a determination of presence or absence of negative beta-lactamase H. influenzae, positive beta-lactamase H. influenzae, M. catarrhalis, and S. pneumoniae. The method includes evaluating the pathogenic diagnosis to determine the following:
In another aspect, a method for diagnosing and/or treating otitis media includes obtaining a test result from an assay performed on a biological sample from a subject that reports presence or absence of negative beta-lactamase H. influenzae, positive beta-lactamase H. influenzae, M. catarrhalis, and S. pneumoniae; applying a decision algorithm to the test result to determine a treatment protocol; administering, recommending administration of, or having administered the treatment protocol; and monitoring patient response to the treatment protocol.
If a type or isolate of H. influenzae is present in the test report or result, then the result or report is further analyzed or inspected to determine the type or isolate of H. influenzae present. In an embodiment, the report or result provides information on presence or absence of positive beta-lactamase H. influenzae. If positive beta-lactamase H. influenzae is present (and, recall, at this point in the algorithm, a determination has been made that S. pneumonia is not present), the report or result is consulted to determine whether M. catarrhalis is present. If positive beta-lactamase H. influenzae and/or M. catarrhalis is/are present, then an antibiotic is not provided or recommended, optionally with a recommendation for or instructions to follow-up if the subject does not improve or worsens in a designated time frame. Optionally, if the subject in the absence of an antibiotic does not improve or worsens in a certain time frame, then a rescue antibiotic may be provided or recommended, where the rescue antibiotic is one having beta-lactamase activity.
With continued reference to
In an embodiment, the methods herein apply a decision algorithm as depicted in any one
In an embodiment, the decision algorithm comprises evaluating a test result or report to determine one or more of the following:
If S. pneumonia is present and negative beta-lactamase H. influenzae is absent and/or no other organisms (such as M. catarrhalis and positive beta-lactamase H. influenzae) are present, then the method comprises providing or recommending to provide immediate antibiotic treatment with an antibiotic that does not require beta-lactamase activity.
With continued reference to
If inspection of the diagnostic test result/report reveals that S. pneumonia is absent and H. influenzae is present, then a determination of whether the H. influenzae is negative beta-lactamase H. influenzae or positive beta-lactamase H. influenzae and whether M. catarrhalis is present or absent is conducted. If positive beta-lactamase H. influenzae and/or M. catarrhalis is/are present then the method comprises providing or recommending to provide delayed antibiotic treatment with an antibiotic with beta-lactamase activity. If neither positive beta-lactamase H. influenzae nor M. catarrhalis is/are present, then the method comprises providing or recommending to provide delayed antibiotic treatment with an antibiotic that does not require beta-lactamase activity.
In an embodiment, the algorithm includes providing or recommending a treatment option from the following options, which apply if S. pneumoniae is not present and:
With continued reference to
Continuing with
Example 1 details a study using the algorithms of
In an embodiment, the subject with otitis media or with AOM is a child or
a pediatric patient, intending a person under the age of 21. In other embodiments, the subject is an infant, with an age between birth and 2 years, a child aged from 2 to 12 years, or an adolescent with an age of from 12 to 21 years. In other embodiments, the subject is an adolescent with an age from 11 to 21 years, which can be further classified into early (ages 11-14 years), middle (ages 15-17 years), and late (ages 18-21 years) adolescence.
In an embodiment, the time frame or “designated time frame” or “certain time frame” mentioned with respect to the methods and algorithms described herein is about 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 60 hours, 72 hours, or 96 hours. In other embodiments, the time frame or “designated time frame” or “certain time frame” mentioned with respect to the methods and algorithms described herein is not more than any of about 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 60 hours, or 72 hours. It will be appreciated that the time frame determined by a medical provider will depend on a number of factors, such as but not limited to, the age of the subject, relevant medical history, current health, length of time of current clinical symptoms, and/or severity of clinical symptoms.
It will be appreciated that the algorithms or portions thereof may be performed by a computing device. The computing device may be a mobile device, a point-of-care instrument, a hand-held instrument, or a diagnostic and/or treatment system.
In step 104, the diagnostic and treatment system presents at least one primary treatment option or protocol. The at least one primary treatment option is generated by a treatment model based on the test input. The treatment model may be implemented using various algorithms. For example, the treatment model may apply a decision algorithm as depicted in any one
At optional step 106, the diagnostic and treatment system presents a secondary treatment option. Additional operations may immediately precede step 106, such as the diagnostic and treatment system receiving follow-on input. The follow-on input may include, for example, information about whether a patient complied with the primary treatment option, whether a patient's symptoms have improved or have worsened following implementation of the primary treatment option, and the amount of time elapsed since provision of or patient compliance with the primary treatment option. In one example, the secondary treatment option may be a rescue antibiotic as described herein.
Each of the step 104 and optional step 106 may be presented on an output interface, such as a digital output interface, for example a website, mobile device, or point-of-care instrument.
The tables below (i.e., Tables 1-1, 1-2, 2-1, 2-2, 3-1, and 3-2) provide additional details on the diagnostic test algorithms. All algorithms may be used in conjunction with clinical decision-making based on a patient's clinical presentation and relevant medical history including but not limited to the following: immunocompromised status, history of recent acute otitis media episodes or recurrent acute otitis media, recent antibiotic use, history of tympanostomy tube placement, otorrhea, concurrent conjunctivitis, severity of infection, medication allergy history, and access to follow-up care if needed.
Observation or delayed prescribing may be considered alternative options to immediate antibiotic therapy regardless of organisms detected given the high spontaneous resolution rates and low complication rates of untreated acute otitis media. In the case of use of observation or delayed prescribing, the rapid diagnostic testing algorithms can be used to guide antibiotic agent choice.
S. pneumoniae
S. pneumoniae + non-beta
H. influenzae
S. pneumoniae + non-beta
H. influenzae + M. catarrhalis
S. pneumoniae + beta
H. influenzae
S. pneumoniae + beta
H. influenzae + M. catarrhalis
S. pneumoniae +
M. catarrhalis
H. influenzae non-beta
H. influenzae non-beta
M. catarrhalis
H. influenzae beta
H. influenzae beta
M. catarrhalis
M. catarrhalis
1Includes S. pneumoniae, H. influenzae, M. catarrhalis.
2An antibiotic to be given if a patient worsens or does not improve within a designated time frame from initial treatment.
3No antibiotic indicated, follow-up in-person or by contacting the clinician or clinician team if patient worsens or does not improve within a designated time frame. Could consider a delayed antibiotic prescription with rescue antibiotic preference as an alternative option. Sometimes referred to as watchful waiting.
4Refer to antibiotic Table A.
5An antibiotic prescribed with the intent to be filled and/or taken by the patient right away.
6Refer to antibiotic Table A.
7An antibiotic prescribed with the intent to be filled and taken if the patient worsens or does not improve within a designated time frame. Sometimes referred to as a safety-net prescription or categorized as watchful waiting.
S. pneumoniae
S. pneumoniae + non-beta lactamase
S. pneumoniae + non-beta lactamase
M. catarrhalis
S. pneumoniae + beta lactamase
S. pneumoniae + beta lactamase
M. catarrhalis
S. pneumoniae + M. catarrhalis
H. influenzae non-beta lactamase
H. influenzae non-beta lactamase
H. influenzae beta lactamase producing
H. influenzae beta lactamase producing +
M. catarrhalis
M. catarrhalis
1Includes S. pneumoniae, H. influenzae, M. catarrhalis.
2An antibiotic to be given if a patient worsens or does not improve within a designated time frame from initial treatment.
3No antibiotic indicated, follow-up in-person or by contacting the clinician or clinician team if patient worsens or does not improve within a designated time frame. Could consider a delayed antibiotic prescription with rescue antibiotic preference as an alternative option. Sometimes referred to as watchful waiting.
4Refer to antibiotic Table A.
5An antibiotic prescribed with the intent to be filled and/or taken by the patient right away.
6Refer to antibiotic Table A.
7An antibiotic prescribed with the intent to be filled and taken if the patient worsens or does not improve within a designated time frame. Sometimes referred to as a safety-net prescription or categorized as watchful waiting.
S. pneumoniae
S. pneumoniae + non-beta
S. pneumoniae + non-beta
M. catarrhalis
S. pneumoniae + beta lactamase
S. pneumoniae + beta lactamase
M. catarrhalis
S. pneumoniae + M. catarrhalis
H. influenzae non-beta lactamase
H. influenzae non-beta lactamase
H. influenzae beta lactamase
H. influenzae beta lactamase
M. catarrhalis
1Includes S. pneumoniae, H. influenzae, M. catarrhalis.
2An antibiotic to be given if a patient worsens or does not improve within a designated time frame from initial treatment.
3No antibiotic indicated, follow-up in-person or by contacting the clinician or clinician team if patient worsens or does not improve within a designated time frame. Could consider a delayed antibiotic prescription with rescue antibiotic preference as an alternative option. Sometimes referred to as watchful waiting.
4Refer to antibiotic Table A.
5An antibiotic prescribed with the intent to be filled and/or taken by the patient right away.
6Refer to antibiotic Table A.
S. pneumoniae
S. pneumoniae + non-beta lactamase
S. pneumoniae + non-beta lactamase
M. catarrhalis
S. pneumoniae + beta lactamase
S. pneumoniae + beta lactamase
M. catarrhalis
S. pneumoniae + M. catarrhalis
H. influenzae non-beta lactamase
H. influenzae non-beta lactamase
H. influenzae beta lactamase
H. influenzae beta lactamase
M. catarrhalis
1Includes S. pneumoniae, H. influenzae, M. catarrhalis.
2An antibiotic to be given if a patient worsens or does not improve within a designated time frame from initial treatment.
3No antibiotic indicated, follow-up in-person or by contacting the clinician or clinician team if patient worsens or does not improve within a designated time frame. Could consider a delayed antibiotic prescription with rescue antibiotic preference as an alternative option. Sometimes referred to as watchful waiting.
4Refer to antibiotic Table A.
5An antibiotic prescribed with the intent to be filled and/or taken by the patient right away.
6Refer to antibiotic Table A.
S. pneumoniae
S. pneumoniae + non-
S. pneumoniae + non-
M. catarrhalis
S. pneumoniae + beta
H. influenzae
S. pneumoniae + beta
H. influenzae +
M. catarrhalis
S. pneumoniae +
M. catarrhalis
H. influenzae non-beta
H. influenzae non-beta
M. catarrhalis
H. influenzae beta
H. influenzae beta
M. catarrhalis
M. catarrhalis
1Includes S. pneumoniae, H. influenzae, M. catarrhalis.
2An antibiotic to be given if a patient worsens or does not improve within a designated time frame from initial treatment.
3No antibiotic indicated, follow-up in-person or by contacting the clinician or clinician team if patient worsens or does not improve within a designated time frame. Could consider a delayed antibiotic prescription with rescue antibiotic preference as an alternative option. Sometimes referred to as watchful waiting.
4Refer to antibiotic Table A.
5An antibiotic prescribed with the intent to be filled and/or taken by the patient right away.
6Refer to antibiotic Table A.
7An antibiotic prescribed with the intent to be filled and taken if the patient worsens or does not improve within a designated time frame; sometimes referred to as a safety-net prescription or categorized as watchful waiting.
S. pneumoniae
S. pneumoniae + non-beta
H. influenzae
S. pneumoniae + non-beta
H. influenzae + M. catarrhalis
S. pneumoniae + beta lactamase
S. pneumoniae + beta lactamase
M. catarrhalis
S. pneumoniae + M. catarrhalis
H. influenzae non-beta lactamase
H. influenzae non-beta lactamase
H. influenzae beta lactamase
H. influenzae beta lactamase
M. catarrhalis
1Includes S. pneumoniae, H. influenzae, M. catarrhalis
2An antibiotic to be given if a patient worsens or does not improve within a designated time frame from initial treatment
3No antibiotic indicated, follow-up in-person or by contacting the clinician or clinician team if patient worsens or does not improve within a designated time frame. Could consider a delayed antibiotic prescription with rescue antibiotic preference as an alternative option. Sometimes referred to as watchful waiting.
4Refer to antibiotic Table A.
5An antibiotic prescribed with the intent to be filled and/or taken by the patient right away.
6Refer to antibiotic Table A.
7An antibiotic prescribed with the intent to be filled and taken if the patient worsens or does not improve within a designated time frame. Sometimes referred to as a safety-net prescription or categorized as watchful waiting.
The algorithms disclosed herein may help a medical care provider determine a treatment protocol for a patient presenting with symptoms of otitis media. The present standard of care does not include identifying the otopathogen(s) causing clinical symptoms of otitis media, nor does it include determining a treatment protocol based on the otopathogen(s) causing clinical symptoms of otitis media. Compared to the current standard of care, the present disclosure enables clinicians to make treatment decisions informed by the presence of absence of various otopathogen(s). The present disclosure enables clinicians to not issue a prescription or to issue a prescription for immediate or delayed antibiotic treatment, as described herein, based on test results as incorporated into the provided algorithms.
The samples, assays, and/or algorithms disclosed herein may form the basis of treating a patient having otitis media. Treatment includes one or more of an immediate antibiotic, a delayed antibiotic, a rescue antibiotic, no antibiotic, observation, and follow-up, each as disclosed herein. An antibiotic may be with or without beta-lactamase activity.
In one example, a nasal sample obtained from a patient is combined with an extraction reagent to produce a test sample. The test sample, or a portion thereof, may be combined with one or more reagents, such as an amplification reagent, and such as to produce an amplification sample. The amplification sample may be subjected to an assay disclosed herein, such as an amplification-based assay that amplifies otopathogenic nucleic acid(s), if present. The amplified nucleic acid, if present, may then be detected. The detection result may be subjected to one or more of the algorithms disclosed herein to guide a treatment protocol. The subject may then be treated for otitis media.
Kits disclosed herein include components for use in one or more of the assays disclosed herein. For example, a kit may be a kit suitable for a PCR-based assay and may include primers or probes complementary to a DNA target (such as otopathogenic nucleic acids). Primers may be provided as a set including at least one forward primer and at least one reverse primer complementary to a DNA target. The kit may also include one or more of a DNA polymerase and deoxynucleoside triphosphates (dNTPs) present in a suitable buffer for nucleic acid amplification and detection. The primers or probes may be specific to one or more of H. influenzae, M. catarrhalis, or S. pneumonia. The primers or probes may be specific to one or more of beta-lactamase producing H. influenzae and non-beta-lactamase producing H. influenza. The primers or probes may be specific for one or more antimicrobial resistance markers or genes, such as ctx-M (blaCTX-M, subgroup 1), kpc (blaKPC), mecA, ndm (blaNDM), oxa-23 (blaOXA-23), oxa-24 (blaOXA-24), oxa-48 (blaOXA-48), oxa-58 (blaOXA-58), tem (blaTEM), or vim (blaVIM). In some embodiments, a kit includes primers specific to all of beta-lactamase producing H. influenzae, non-beta-lactamase producing H. influenzae, M. catarrhalis, and S. pneumonia. More than one set of primers or probes capable of amplifying one organism may be included in a kit.
The present standard of care does not include identifying the otopathogen(s) causing clinical symptoms of otitis media. Instead, treatment decisions are made in the absence of information about which otopathogen(s) are present and which are absent in a patient. Compared to the standard of care, the presently disclosed kits, and related assays, enable the easy and rapid identification of likely otopathogen(s) responsible for otitis media. The presently disclosed kits, and related assays, combine primers or probes directed to identifying common otopathogen(s) responsible for otitis media, or the otopathogen(s) whose presence or absence has a notable impact on a treatment decision or protocol. Such otopathogen(s) may include beta-lactamase producing H. influenzae, non-beta-lactamase producing H. influenzae, M. catarrhalis, and S. pneumonia.
The following examples are illustrative in nature and are in no way intended to be limiting.
This example demonstrates that testing of nasopharyngeal (NP) samples using a polymerase chain reaction based assay (an example of a rapid diagnostic test or RDT) can effectively exclude the presence of organisms in middle ear fluid and is useful to individualize care.
Two algorithms for AOM management based on NP bacterial otopathogens were developed, and are depicted in
The algorithm that used immediate, delayed prescribing, and observation based on pathogen (
While a number of exemplary aspects and embodiments have been discussed above, those of skill in the art will recognize certain modifications, permutations, additions, and sub-combinations thereof. It is therefore intended that the following appended claims and claims hereafter introduced are interpreted to include all such modifications, permutations, additions, and sub-combinations as are within their true spirit and scope.
This application claims priority to U.S. Application No. 63/313,687, filed Feb. 24, 2022, and to U.S. Application No. 63/335,801, filed Apr. 28, 2022, the contents of which are incorporated herein in their entireties.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2023/063218 | 2/24/2023 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 63313687 | Feb 2022 | US | |
| 63335801 | Apr 2022 | US |
